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Objective: We established a COPD taskforce for early detection, diagnosis, treatment, and 
intervention. We implemented a pilot intervention with a prospective and longitudinal design 
in a regional city. This study evaluates the usefulness of the COPD taskforce and intervention 
based on COPD case detection rate and per capita medical costs.
Method: We distributed a questionnaire to all 8,878 inhabitants aged 50–89 years, resident in 
Matsuura, Nagasaki Prefecture in 2006. Potentially COPD-positive persons received a pulmonary 
function test and diagnosis. We implemented ongoing detection, examination, education, and treat-
ment interventions, performed follow-up examinations or respiratory lessons yearly, and supported 
the health maintenance of each patient. We compared COPD medical costs in Matsuura and in the 
rest of Nagasaki Prefecture using data from 2004 to 2013 recorded by the association of Nagasaki 
National Health Insurance Organization, assessing 10-year means and annual change.
Results: As of 2014, 256 people have received a definitive diagnosis of COPD; representing 
31% of the estimated total number of COPD patients. Of the cases detected, 87.5% were mild 
or moderate in severity. COPD medical costs per patient in Matsuura were significantly lower 
than the rest of Nagasaki Prefecture, as was rate of increase in cost over time.
Conclusion: The COPD program in Matsuura enabled early detection and treatment of COPD 
patients and helped to lower the associated burden of medical costs. The success of this pro-
gram suggests that a similar program could reduce the economic and human costs of COPD 
morbidity throughout Japan.
Keywords: chronic obstructive pulmonary disease, systematic intervention, case detection rate, 
medical cost, longitudinal study
Introduction
COPD involves inflammation of the trachea and real progressive pulmonary destruction 
caused by long-term exposure to inhaled pollutants such as cigarette smoke. COPD 
features an accelerating drop in the airflow limitation and in pulmonary function, and 
it is an increasingly important factor of morbidity and mortality.1,2 By 2020, COPD 
is predicted to be the third leading cause of death throughout the world.3 In Japan 
in 2012, COPD was the ninth leading cause of total deaths, and eighth in men; this 
number increases yearly.4 The increase in COPD patients is predicted to increase as 
the population ages. In addition, large medical costs are incurred by the deteriorat-
ing condition of COPD patients during the progress of the disease.5 Therefore, early 
detection and early treatment are important for slowing the increase in COPD patients 
and reducing the related financial burden.
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Several reports giving data on the prevalence of COPD 
have been recently published. The Latin American Project for 
the Investigation of Obstructive Lung Disease (PLATINO) 
and Burden of Obstructive Lung Disease (BOLD) initiative 
studies of COPD prevalence have reported regional differences 
worldwide.6,7 Prevalences as high as 12% and as low as 7% 
have recently been reported, with most countries falling in the 
7%–9% range.8 The Nippon COPD Epidemiology (NICE) 
Study found a prevalence of 8.6%.9 The study estimated that at 
least 5.3 million people in Japan had COPD but found that only 
approximately 260,000 people (4.9%) were receiving treat-
ment, a very low figure.10 COPD remains underdiagnosed and 
undertreated worldwide.11,12 The reasons for this include low 
awareness of COPD,13 the slow spread of spirometry for use 
in definitive diagnoses,11 and the lack of subjective symptoms 
in middle-aged male smokers with mild cases of COPD.14 In 
addition, most COPD epidemiologic studies used data derived 
from a random sample without directly investigating all inhab-
itants of the area, are retrospective studies from databases, and 
use almost entirely cross-sectional techniques.6–9,15,16
COPD requires early detection and early treatment. 
Therefore improving the recognition of COPD is necessary to 
increase consultations. In addition, promoting the continuous 
detection of potential patients and preventing symptomatic 
exacerbation is important. However, few studies have evalu-
ated the effects of sufficiently long-term interventions.17,18
There are many useful reports about COPD treat-
ment interventions. The treatment of COPD patients with 
long-acting bronchodilators could alleviate the deteriora-
tion of pulmonary function with age,19,20 and studies have 
indicated that smoking cessation can inhibit decreased 
pulmonary function.21–24 Many reports have shown that 
rehabilitation interventions significantly improved COPD 
patient outcomes.25–27 Early detection and diagnosis of COPD 
and interventions including medical therapy, smoking cessa-
tion, and rehabilitation combine in an attempt to prevent the 
development and progression of the disease.
Because of the high degree of deterioration in quality of 
life and the serious economic consequences of COPD, the 
Japanese Ministry of Health, Labour and Welfare created a 
comprehensive policy for the prevention and management 
of COPD known as “Kenko Nihon [Healthy Japan] 21”. 
However, aside from describing methods of increasing 
the awareness of COPD, this policy contains no specific 
strategies.28 As a result, local municipalities have neither 
specific initiatives to promote the early detection and treat-
ment of COPD, smoking cessation policies, nor initiatives 
to promote continuous treatment of the disease.
In 2006, we initiated a COPD taskforce in the city of 
Matsuura in Nagasaki Prefecture and created an original COPD 
intervention system.13 The taskforce consisted of members of 
the medical association, the local government, and academia. 
Members of the public health center, the local government, a 
local medical association and a university jointly conducted 
COPD examinations on all inhabitants aged 50 years and 
older in a single city. A major hospital provided interventions 
to enable the early diagnosis of patients suspected of having 
COPD, their family doctors initiated treatment, and public 
health centers and the university jointly performed follow-up 
examinations (Figure 1). In this long-term community-based 
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Follow-up checkups#: once per year
COPD classes# (smoking cessation classes, health classes): four times per year
Patient meetings#: twice per year
Establishment of 
medical systems
Preparation and displaying of medical posters




Lectures and publications* (ongoing series); open lectures for city residents*: once per year
Hosting of training workshops (guidance on methods for respiratory examinations; respiratory rehabilitation): once per year
Preparation of pamphlets on rehabilitation
Explanation of the results of COPD checkups to residents and medical staff: once per year 
Figure 1 Overview of the educational COPD intervention activities.
Notes: #Follow-up checkups, COPD classes and patient meetings were conducted for persons with a definitive diagnosis of COPD and residents with potential COPD. 
*City publications were distributed to all households in Matsuura and open lectures for city residents were publicized among all residents in Matsuura, both of which could 
be viewed and/or attended. adapted from asai M, Tanaka T, Kozu r, et al. effect of a COPD Intervention on COPD awareness in a regional City in Japan. Intern Med. 
2015;54(2):163–169.13
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study implemented by the COPD taskforce, we investigated 
the effects of cooperation between one city’s hospitals and 
clinics on case detection rate and on the medical costs of all 
inhabitants aged 50 years and older, as well as preventative 
measures including early detection and treatment, continu-
ous treatment, and smoking cessation. To our knowledge, no 
other study of this kind has been published to date.
The aim of this study was to verify the usefulness of the 
COPD taskforce and intervention.
We investigated the case detection rate and COPD-
associated medical costs of all COPD patients diagnosed by 
this system to date.
Methods
study design and setting
This study was a community-based longitudinal study of 
all inhabitants aged 50–89 years in the city of Matsuura, 
Nagasaki Prefecture (n=8,878 as of September 2006). This 
study was conducted with the approval of the Human Ethics 
Review Committee of Nagasaki University Graduate School 
of Biomedical Sciences (approval number: 1308056). The 
participants’ data were allocated a code to protect their 
identities, and all information was kept confidential. All 
participants provided written consent.
summary of the COPD taskforce
Creation of the COPD taskforce and education 
campaign
We established the COPD taskforce in cooperation with 
the Kita Matsuura Medical Association and the Nagasaki 
Prefectural Kenhoku Health Center in Matsuura.13 Its objec-
tives were as follows. 1) The early detection and treatment 
of COPD, and continuous intervention for COPD patients to 
prevent the progression of COPD. 2) Increasing awareness 
of COPD to ensure that community inhabitants had a proper 
understanding of COPD. 3) Creating preventative measures 
such as smoking cessation programs and policies to prevent 
people being exposed to tobacco smoke. We developed edu-
cational material such as brochures and poster notices about 
COPD for the medical office in Matsuura to increase COPD 
recognition, and we held a study session (Figure 1).
COPD examination and definitive diagnosis and 
actions for early detection
To efficiently select potential COPD patients from the 
community, we mailed a self-administered eleven-item pre-
interview questionnaire (11-Q) to all inhabitants aged 50–89 
years as initial screening.29 The 11-Q consists of eleven items 
related to respiratory symptoms and disease background.29 
It has a high degree of repeatability, sensitivity, and speci-
ficity, which suggests it is useful as a screening method for 
COPD.29 In line with previous studies, we set the cut-off point 
at 5 points, and patients scoring 5 or more points underwent 
secondary screening.29
Secondary screening consisted of pulmonary function 
tests, physical measurements (height, weight, and body 
mass index), and an interview to determine smoking status 
and the Brinkman Index (BI). The pulmonary function tests 
were conducted using an electronic spirometer (Autospiro 
AS-507; Minato Medical Science Co., Osaka, Japan). Vital 
capacity (VC), VC predicted, forced vital capacity (FVC), 







 predicted were measured. Measurements were 
performed according to the American Thoracic Society and 
European Respiratory Society pulmonary function testing 
guidelines.30 Those patients whose pulmonary function test 
results indicated an FEV
1
/FVC of ,0.7 or who reported 
subjective symptoms during their interview and expressed 
the desire for a definitive diagnosis were referred to a local 
foundation hospital where a specialist in pulmonary medi-
cine performed reversibility tests using bronchodilators and 
computed tomography. COPD examinations were conducted 
in 2006 and 2011 (Figure 1).
In addition, we asked each medical office in Matsuura to 
use a simple interview question during outpatient consultations 
for the purpose of early COPD detection. We established a 
COPD examination booth at the medical health checkup and 
the health festival in 2007 and subsequently provided a booth 
at these events yearly from 2012 until present (Figure 1). When 
attending the booth, the applicants received a pulmonary 
function test; individuals who tested positive were advised 
to undergo a complete checkup and were integrated with the 
COPD patient early detection and treatment system.
Intervention for patients with a definitive diagnosis 
of COPD
The COPD taskforce conducted follow-ups for patients with 
a definitive diagnosis of COPD using a system of coopera-
tion between hospitals and clinics. Family doctors played a 
central role in this system. They cooperated with medical 
facilities capable of providing a definitive COPD diagnosis, 
performing respiratory rehabilitation, and accommodating 
inpatients to provide continuous care. Medical information 
held by family doctors, cooperating medical facilities, and 
public health centers was integrated so that COPD patient 
data could be comprehensively managed.





When indicated, family doctors referred COPD patients 
to medical facilities capable of providing outpatient smok-
ing cessation services, where the patients received smoking 
cessation guidance. The system was created so that patients 
could receive care in accordance with Japanese respiratory 
society guidelines. 31 The contents follow the GOLD COPD 
guidelines, eg, instruction in smoking cessation is important 
in Stage I, and the use of the short-acting bronchodilator is 
recommended for symptom reduction as needed. Improve-
ment of quality of life and exercise tolerance becomes the 
aim in addition to symptom reduction in Stage II, and a long-
acting bronchodilator and pulmonary rehabilitation are rec-
ommended. The prevention of exacerbations is important in 
Stage III and IV, and inhaled corticosteroids are considered in 
addition to the treatment mentioned above.31 The list of hos-
pitals was advertised in local government offices, hospitals, 
and the community to inform local inhabitants of the types 
of care available and the facilities where it was provided. 
Patients diagnosed with COPD who desired treatment were 
immediately provided with drug therapy and smoking ces-
sation guidance by their family doctor. Follow-up checkups 
providing health guidance, pulmonary function tests, and 
interviews were conducted once per year in cooperation with 
the university and public health centers (Figure 1).
In the respiratory classroom, educational courses were 
held two to four times yearly for patients and their family on 
topics including COPD pathology, smoking cessation, and 
pulmonary rehabilitation (including exercise training, upper 
and lower limb muscular strength exercises, and breathing 
control). These courses were provided by a doctor, a com-
munity health nurse, and a physical therapist. A workshop 
for the region’s doctors and medical staff was held every year 
including classes on pulmonary function testing or pulmonary 
rehabilitation, to ensure the necessary understanding and skill 
to implement COPD treatment (Figure 1).
The estimated quantity and prevalence  
of COPD patients
Based on the number of COPD patients who received a 
definitive diagnosis, we calculated the estimated number of 
COPD patients in Matsuura and the prevalence of COPD. 
The estimated number of COPD patients was calculated by 
the 11-Q positive rate (the number of respondents with more 
than five points divided by the number of 11-Q effective 
respondents) multiplied by the pulmonary function test posi-
tive rate (the number of possible COPD cases divided by the 
number that received a pulmonary function test) multiplied 
by the COPD diagnosis decision rate (the number of COPD 
diagnosed divided by the number of possible COPD) divided 
by the target population.
The COPD prevalence was calculated using the percent-
age of the estimated number of COPD patients in the target 
population. Prevalence was also calculated separately for sex, 
age, and smoking history. We calculated prevalence by smok-
ing history using the BI measured in question 1 of 11-Q.
Medical costs of COPD
To assess the financial benefits, if any, provided by our inter-
vention, the medical costs associated with COPD in each city 
area in Nagasaki Prefecture were taken from the database of 
the Nagasaki National Health Insurance Organizations. Data 
were retrieved covering 10 years spanning 2004 through to 
2013. Because of variation in the number of the members of 
National Health Insurance and in the population of cities, we 
calculated the COPD medical costs per one National Health 
Insurance member 50 years or older, and compared costs per 
patient residing in Matsuura with costs in the rest of Nagasaki 
Prefecture except Matsuura. In addition, we added the cost 
for taskforce to the medical cost of Matsuura. We compared 
a 10-year mean price as well as the annual change in medical 
costs. Because medical costs are recorded using the location 
of households, costs are therefore counted accurately and 
attributed to the correct region.
statistical analysis
All data were checked for normality using the Shapiro–Wilk 
test. The comparison of measures of participation in COPD 
screening examinations was carried out using the chi-square 
test. We used a Student’s t-test and Mann–Whitney U-test to 
compare the averages of medical costs and used an analysis 
of covariance to compare the annual change.
Statistical processing was performed using IBM SPSS 
Statistics 21.0J for Windows (IBM Corporation, Armonk, 
NY, USA). Statistical significance was set as a probability 
of less than 5%.
Results
COPD examination
During the COPD examination that we carried out in 2006, 
140 people received a definitive diagnosis of COPD (Figure 2). 
The initial screening had a low ratio of male participants and 
individuals in the 50–59 year-old age group. The 50–59 year-
old age group also had low participation in the secondary 
screening. In addition, the answers to 11-Q revealed that many 
people with some kind of symptom participated, and there was 
low participation among ex- and current smokers (Table 1).
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In the COPD examination that we carried out in 2011, 
48 COPD patients were newly targeted for follow-up and 
were registered (Figure 2). In the first screening, the ratio 
of participation was low in the youngest generation. Fewer 
women than men participated in the second screening, and 
there were no longer differences in reporting of symptoms 
in the 11-Q or smoking (Table 1).
The estimated number and prevalence  
of COPD patients
In the 2006 COPD examination, the prevalence was 9.2% 
(Figure 3A). Of the 814 estimated total COPD patients in 
Matsuura, we were able to detect 17% in this examination. 
COPD prevalence by sex was 17.6% in men and 2.1% in 
women (Figure 3A). The prevalence by age was 4.7% in the 
50–59 year-old age group, 7.9% in the 60–69 year-old age 
group, 12.1% in the 70–79 year-old age group, and 25.5% in 
the 80+ year-old age group (Figure 3B). The prevalence by 
smoking status was 1.8% of non-smokers and 20.5% of smok-
ers, and by BI was 3.4% of 1–400, 14.4% of 401–800, 32.3% 
of 801–1,200, and 36.6% of 1,201 or greater (Figure 3C).
Progress of the COPD taskforce
Using data from the database of the Nagasaki National Health 
Insurance Organizations, an average of eight outpatients 
consulted the medical institution each month in 2004, and 
eleven outpatients consulted the medical institution in 2005. 
After the COPD examination that we carried out in 2006, 
COPD patients were not identified by the simple outpatient 
questionnaire implemented by each medical office. How-
ever, 13 patients were found by participation in the specific 
health checkup in 2007. Subsequently, 14 cases of COPD 
were found at this checkup in 2012, 28 patients in 2013, and 
eleven patients in 2014. As a result, the number of patients 

Figure 2 (Continued)





targeted for follow-up increased to 256 in 2014, reaching 
31% of the 814 predicted COPD patients in 2006 (Figure 4). 
In addition, using the GOLD Stage classification, at the time 
of follow-up registration, patients at Stages I and II, equal to 
mild or moderate grade symptoms, comprised 87.5% of the 
total patients.
Medical costs of COPD
The total costs of the COPD screening in the task-force was 
2,240,000 yen for mail and personnel costs. Besides, the annual 
action needed an average of approximately 400,000 yen. 
 Figure 5 showed a comparison between Matsuura and the rest 
of Nagasaki Prefecture for the average COPD medical costs 
in 10 years of one National Health Insurance member 50 years 
or older. And the data of Matsuura are shown including 
cost of the taskforce. A Student’s t-test showed that the 
cost in Matsuura was significantly lower than for the rest 
of Nagasaki Prefecture (49.3±25.2 yen/month versus [vs] 
82.7±37.0 yen/month, P,0.05). There was no significant 
difference in outpatient medical costs (48.6±24.9 yen/month 
vs 48.8±19.3 yen/month, P=0.739), but hospitalization costs 
were significantly lower in Matsuura (1.82±5.8 yen/month 
vs 34.0±18.9 yen/month, P,0.001).
The comparison using analysis of covariance of the annual 
change of COPD medical costs shows that Matsuura had a 
significantly lower rate of increase in COPD medical costs 
than the rest of Nagasaki Prefecture (P,0.01) (Figure 6).
Discussion
By 2014, the COPD taskforce reached and provided care 
to 31% of the estimated total number of COPD patients 
calculated at the start of the investigation. Approximately 

Figure 2 Flowchart of the COPD screening and diagnosis procedure in Matsuura, Japan.
Abbreviations: 11-Q, eleven-item pre-interview questionnaire; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.




systematic intervention for chronic obstructive pulmonary disease
266,000 people are receiving treatment for COPD in Japan,10 
comprising only 5% of the estimated 5.3 million total 
Japanese COPD patients calculated in the NICE study.9 By 
comparison, we reached 31% of all COPD patients in one 
city and provided follow-up education and treatment, while 
lowering the growth rate of COPD cost-of-care, demonstrat-
ing the utility and financial viability of the approach imple-
mented by the COPD taskforce. In addition, we consider it 
to be very useful that the taskforce was able to enroll 140 
patients in primary care at a time in comparison with the 
consultation number of outpatients before the COPD task-
force was implemented.
Many epidemiologic studies have been reported on 
COPD, including prevalence investigations, but bias occurs 
in the criteria for selection because these studies do not 
investigate all inhabitants of the relevant area.6–9 However, in 
an initial screening investigation using the simple 11-Q inter-
view list, all inhabitants can be surveyed. In addition, there is 
a low burden on participants because the time required for this 
simple self-administered questionnaire is only approximately 
5 minutes. This study demonstrated the benefit of such a 
convenient time-efficient screening questionnaire, because 
the 11-Q response rate was greater than 50%.
Kida et al have reported that a screening examination 
using a pulmonary function test alongside 11-Q is useful 
for early detection of COPD in primary care settings.29 Oike 
et al reported that this combined screening examination was 
more effective for COPD patient detection than conventional 
preventative medical examinations in Japan.32 In addition, it 
has been reported that primary care COPD screening using 
questionnaires such as the International Primary Care Air-
ways Guidelines questionnaire and the simple expression 
pulmonary function test device was more useful for patient 
detection and medical cost reduction than a pulmonary func-
tion test.33–36 These reports further indicate the utility of the 
COPD screening method used in this study.
We developed brochures for medical personnel and the 
public and held a workshop for medical personnel while 
providing continuous support for the COPD patients identi-
fied in 2006 so that diagnosis and treatment of COPD would 
be augmented by primary care clinics identifying further 
COPD patients. However, we did not see a meaningful 












Male 2,028 (49) 2,099 (51) 1,537 (38) 2,515 (62)
Female 2,442 (51) 2,309 (49) 1,777 (39) 2,754 (61)
age (years)
50–59 1,608 (45) 1,931 (55) 999 (33) 2,050 (67)
60–69 1,349 (55) 1,090 (45) 1,186 (41) 1,718 (59)
70–79 1,404 (52) 1,253 (48) 1,045 (43) 1,372 (57)
80 109 (45) 134 (55) 84 (39) 129 (61)
PFT
sex
Male 401 (35) 763 (65) 167 (30) 400 (70)
Female 234 (34) 452 (66) 88 (25) 267 (75)
age (years)
50–59 163 (24) 521 (76) 69 (27) 186 (73)
60–69 212 (40) 313 (60) 91 (29) 225 (71)
70–79 239 (41) 349 (59) 90 (28) 232 (72)
80 21 (40) 32 (60) 4 (14) 24 (86)
smoking
Current/former 411 (33) 840 (67) 131 (29) 323 (71)
none 224 (37) 375 (63) 124 (27) 344 (73)
respiratory symptom
Present 586 (36) 1,067 (64) 235 (28) 608 (72)
none 49 (25) 148 (75) 20 (25) 59 (75)
Notes: Data are number (%) of subjects. COPD screening expresses a questionnaire and a pulmonary function test. Based on an answer to 11-Q, smoking (question 1) and 
respiratory symptom (questions 3–7).
Abbreviations: 11-Q, eleven-item pre-interview questionnaire; PFT, pulmonary function test.






Figure 3 Prevalence of COPD in Matsuura, 2006.
Notes: (A) COPD prevalence for all Matsuura residents and subdivided by sex, (B) COPD prevalence by generation, (C) COPD prevalence by smoking status and BI score.
Abbreviation: BI, Brinkman Index.
Figure 4 number of newly diagnosed COPD patients each year from 2006 to 2014 in Matsuura.
Note: gray represents newly enrolled patients, while white represents previously enrolled patients. 
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Figure 5 Comparison of the average cost of medical care for managing COPD in 10 years of one national health Insurance member aged 50 years or older in Matsuura 
and in the rest of nagasaki Prefecture.
Notes: The COPD medical costs were calculated for national health Insurance members 50 years or older. The data of Matsuura are shown including a cost of the 
taskforce. The slanted line bar represents COPD medical costs per patient in the whole of nagasaki Prefecture except Matsuura, and the dot bar represents the COPD 
medical costs in Matsuura.
Abbreviation: ns, not significant.
Figure 6 Comparison of average per capita national health Insurance cost of COPD medical treatment in Matsuura and the rest of nagasaki Prefecture in 50–80 year-old 
patients.
Notes: The data of Matsuura are shown including a cost of the taskforce. The solid line represents the medical costs in Matsuura, and the dashed line represents the medical 
costs in the rest of Nagasaki Prefecture. The straight lines are regression lines of these costs. Analysis of covariance demonstrated a significant difference between these 
two trends (P,0.01).





increase in COPD patients identified by primary care clinics 
between 2007 and 2010. We believe this is due to the com-
plexity of primary care duties and by time constraints that 
preclude performing a pulmonary function test.
Consequently, in 2011, we again attempted to identify 
potential COPD patients through the investigative screen-
ing of all residents of Matsuura aged 50 years or older. It 
was subsequently possible to increase the number of COPD 
patients enrolled yearly by gathering the participants of 
the investigation in the event that a lot of participants were 
more likely to be anticipated. However, there may be the 
suggestion of an improvement in COPD patient detection 
in primary care settings in Matsuura, because recently there 
has been a report on the usefulness of primary care COPD 
screening and of a pulmonary function test performed by a 
trained nurse for diagnosing COPD.33–37
The COPD prevalence of 9.2% in all subjects aged 
50 years or older is similar to a previous study.8,9 In addi-
tion, similar results were found relating to sex, generation, 
and smoking status, with higher COPD prevalence among 
smokers, older adults, and men.
During our trial, Matsuura was able to control COPD 
medical costs, and in particular those derived from hospital-
ization, when compared with the rest of Nagasaki Prefecture, 
and it had a significantly lower annual rate of increase in 
COPD medical costs. A report examining COPD medical 
costs in Japan found the estimated total cost of COPD to 
be 805.5 billion yen (US$6.8 billion) per year, including 
645.1 billion yen (US$5.5 billion) in direct costs and 
160.4 billion yen (US$1.4 billion) in indirect costs.38 COPD 
brings a high economic burden, and costs associated with 
hospitalization appear to account for the majority of this 
burden. Darnell et al reported that costs connected to hos-
pitalization accounted for US$18.7 million out of a total of 
US$21.4 million in COPD-related medical costs in the Cin-
cinnati Veteran’s Administration Medical Center.39 Breunig 
et al reported that of the $29.5 billion direct cost of COPD 
in the United States, the overhead costs were predicted to 
be $20.4 billion, and a maximum of 70% of the direct costs 
were caused by hospitalization in conjunction with the 
exacerbation of COPD symptoms.12 In addition, in the report 
that examined COPD medical costs by GOLD Stage, there 
was no significant difference from the control group (non-
COPD) for Stage I, but the medical costs were significantly 
higher than the control group for patients worse than 
Stage II, and the increase in hospitalization costs was par-
ticularly large.40 In the report examining pneumonia among 
the older adults and the medical costs of COPD, COPD 
patients had a sixfold greater incidence of pneumonia when 
compared with patients without COPD, and their medical 
costs were significantly higher.41
Decreasing hospitalization rates will help to control the 
medical costs of COPD, and the results of this study are 
consequently very relevant. Medical costs were kept low 
because COPD was discovered at an early stage through 
examination, and early treatment interventions such as 
smoking cessation were therefore possible. Matsuura was able 
to slow the progress of COPD and prevent acute exacerbation 
when compared with other cities. Physician recognition of 
COPD increased because of an educational course. There-
fore we think that the treatment guidelines promoted COPD 
recognition in primary care. We also believe that the high 
recognition of COPD among Matsuura inhabitants contributed 
to the reduced medical costs.13 Because educational activities 
for local inhabitants, including COPD examination and 
respiratory lessons, were carried out regularly, understanding 
of COPD was high and a positive environment was created for 
commencing treatment. This positive environment increased 
treatment rates and contributed to the comparatively reduced 
medical costs. In addition, it is a very important result that the 
increase in medical costs was lower than in other cities, even 
though the number of follow-up patients treated in Matsuura 
increased yearly. This result strongly demonstrates the useful-
ness of the COPD taskforce.
Limitations of this study include that it applies only to 
individuals 50 years or older, making it difficult to compare 
directly with other studies because most previous studies 
were intended for individuals 40 years or older. In addition, 
selection bias was introduced because individuals could 
choose whether to participate in each screening. Matsuura’s 
COPD patients were detected by examination, but, as for the 
patients of other cities, COPD was found by medical institu-
tion. Thus, lead time bias exists among the COPD patients 
detected in these two groups. In addition, the data on medical 
costs use cases where COPD was registered as the primary 
disease; the COPD frequency among patients registered 
under other diseases is unknown. Further we are unable 
to provide data on the total medical costs for each COPD 
patient because we are unable to determine the medical costs 
of treatment of other co-morbidities. Also, because COPD 
prevalence, severity, recognition, demographic, health, and 
socioeconomic profiles in cities are unidentified and the 
number of respiratory specialists varies, other factors may 
have influenced medical costs. Because we did not analyze 
it in detail, it is not revealed which element of the activity 
of the taskforce influenced a result.




systematic intervention for chronic obstructive pulmonary disease
Our study shows that COPD examination using the simple 
11-Q questionnaire for all inhabitants extracted many COPD 
patients, and we were able to tie this in to early detection 
and early treatment. In addition, we suggested the possibility 
that it is possible to control the medical costs of COPD by 
continuously advancing COPD intervention.
Conclusion
For all inhabitants of Matsuura 50 years or older, COPD 
screening using the simple 11-Q questionnaire and a subse-
quent pulmonary function test enabled early detection and 
early treatment of COPD patients. During this time, Matsuura 
had a significantly lower increase in COPD-associated 
expenses than surrounding cities, suggesting that programs 
such as ours are cost-effective and publicly beneficial inter-
ventions that could be implemented throughout Japan.
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